MétaCan
Menu
Back to cohort
Record W4415716847 · doi:10.1016/j.bpobgyn.2025.102673

Fetal therapy with mTOR inhibitors in cardiac rhabdomyoma and lymphatic malformations

2025· review· en· W4415716847 on OpenAlexaff
Nikan Zargarzadeh, Pegah Rashidian, Tishi Shah, Greg Ryan, Yalda Afshar

Bibliographic record

VenueBest Practice & Research Clinical Obstetrics & Gynaecology · 2025
Typereview
Languageen
FieldMedicine
TopicTuberous Sclerosis Complex Research
Canadian institutionsMount Sinai Hospital
Fundersnot available
KeywordsEverolimusTuberous sclerosisSirolimusPI3K/AKT/mTOR pathwayPopulationRhabdomyomaLymphatic systemRadiofrequency ablationFetal surgery

Abstract

fetched live from OpenAlex

Fetal therapy has advanced with novel pharmacological approaches to address congenital tumors and malformations, including cardiac rhabdomyomas and lymphatic malformations (LMs). Cardiac rhabdomyomas, often associated with tuberous sclerosis complex (TSC), can lead to significant morbidity due to arrhythmias, left or right ventricular outflow tract obstruction and heart failure, particularly in neonates. LMs, resulting from abnormal development of the lymphatic system, can cause considerable morbidity, including airway obstruction, disfigurement, recurrent infections, bleeding into cysts, and impaired function of affected organs, depending on location. Recent therapies involving mammalian target rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, offer promising interventions for these conditions. As mTOR inhibitors target dysregulated cell growth and angiogenesis, they can effectively reduce the size of both cardiac rhabdomyomas and LMs in-utero . Clinical studies in the pediatric population have shown that mTOR inhibitors promote regression of cardiac rhabdomyomas, leading to improved cardiac function, and similarly reduce the size of lymphatic malformations, thereby decreasing the need for surgical or interventional procedures. Sirolimus has also shown efficacy in treating complex LMs and is increasingly being used as a first line agent alone as well as in conjunction with other treatment modalities like surgery and sclerotherapy. Despite potential side effects, including gastrointestinal discomfort and an increased risk of infection, the risk–benefit ratio should be carefully evaluated on an individual patient basis. This review examines current evidence supporting the use of mTOR inhibitors in fetal therapy, highlighting their ability to mitigate postnatal complications and improve long-term outcomes. Further research is needed to optimize dosing protocols and assess the long-term safety of these therapies in the fetal population. • mTOR inhibitors (sirolimus/everolimus) are emerging as promising non-invasive fetal therapies for cardiac rhabdomyomas and lymphatic malformations, especially when surgery is not feasible. • Transplacental administration of sirolimus has demonstrated tumor size reduction and symptom relief in fetuses with severe disease, supporting its use as a prenatal medical intervention. • Safety data are encouraging but limited—adverse effects like immunosuppression, leukopenia, and hyperlipidemia must be closely monitored in both mother and fetus.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.015
metaresearch head score (Gemma)0.172
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Research integrity
Consensus categoriesResearch integrity
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.980
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0150.172
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0050.001
Bibliometrics0.0040.007
Science and technology studies0.0000.002
Scholarly communication0.0000.001
Open science0.0010.001
Research integrity0.0020.007
Insufficient payload (model declined to judge)0.0000.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.250
GPT teacher head0.527
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBest Practice & Research Clinical Obstetrics & GynaecologySame topicTuberous Sclerosis Complex ResearchFrench-language works237,207